Genor Biopharma Secures NMPA Approval for Lerociclib to Treat Advanced Breast Cancer

Reuters

2025/05/29

Genor Biopharma Secures NMPA Approval for Lerociclib to Treat Advanced Breast Cancer

Genor Biopharma Holdings Ltd. has announced that the China National Medical Products Administration (NMPA) has granted approval for the new drug application of Lerociclib (GB491). This novel, highly potent, selective oral bioavailable cyclin-dependent kinases 4 and 6 inhibitor (CDK4/6i) has been co-developed by Genor Biopharma and G1 Therapeutics Inc. It is designed for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer. Lerociclib will be used in combination with an aromatase inhibitor as initial endocrine-based therapy, or with fulvestrant in patients whose disease has progressed following endocrine therapy. This approval represents a significant milestone for Genor Biopharma and showcases the successful collaboration with G1 Therapeutics Inc.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genor Biopharma Holdings Ltd. published the original content used to generate this news brief on May 29, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2539723716"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539723716\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2539723716?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-29 16:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539723716","market":"nz","top_or_hot":-1,"title":"Genor Biopharma Secures NMPA Approval for Lerociclib to Treat Advanced Breast Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Genor Biopharma Secures NMPA Approval for Lerociclib to Treat Advanced Breast Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Genor Biopharma Holdings Ltd. has announced that the China National Medical Products Administration (NMPA) has granted approval for the new drug application of Lerociclib (GB491). This novel, highly potent, selective oral bioavailable cyclin-dependent kinases 4 and 6 inhibitor (CDK4/6i) has been co-developed by Genor Biopharma and <a href=\"https://laohu8.com/S/GTHX\">G1 Therapeutics Inc.</a> It is designed for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer. Lerociclib will be used in combination with an aromatase inhibitor as initial endocrine-based therapy, or with fulvestrant in patients whose disease has progressed following endocrine therapy. This approval represents a significant milestone for Genor Biopharma and showcases the successful collaboration with G1 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genor Biopharma Holdings Ltd. published the original content used to generate this news brief on May 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genor Biopharma Secures NMPA Approval for Lerociclib to Treat Advanced Breast Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenor Biopharma Secures NMPA Approval for Lerociclib to Treat Advanced Breast Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-29 16:59</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Genor Biopharma Secures NMPA Approval for Lerociclib to Treat Advanced Breast Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Genor Biopharma Holdings Ltd. has announced that the China National Medical Products Administration (NMPA) has granted approval for the new drug application of Lerociclib (GB491). This novel, highly potent, selective oral bioavailable cyclin-dependent kinases 4 and 6 inhibitor (CDK4/6i) has been co-developed by Genor Biopharma and <a href=\"https://laohu8.com/S/GTHX\">G1 Therapeutics Inc.</a> It is designed for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer. Lerociclib will be used in combination with an aromatase inhibitor as initial endocrine-based therapy, or with fulvestrant in patients whose disease has progressed following endocrine therapy. This approval represents a significant milestone for Genor Biopharma and showcases the successful collaboration with G1 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genor Biopharma Holdings Ltd. published the original content used to generate this news brief on May 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物醫藥B類股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL8XC61z:1","article_id":"2539723716","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539723716","pubTimestamp":1748509188,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Genor Biopharma Holdings Ltd. has announced that the China National Medical Products Administration  has granted approval for the new drug application of Lerociclib . This novel, highly potent, selective oral bioavailable cyclin-dependent kinases 4 and 6 inhibitor  has been co-developed by Genor Biopharma and G1 Therapeutics Inc. It is designed for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative  locally advanced or metastatic breast cancer. Lerociclib will be used in combination with an aromatase inhibitor as initial endocrine-based therapy, or with fulvestrant in patients whose disease has progressed following endocrine therapy. This approval represents a significant milestone for Genor Biopharma and showcases the successful collaboration with G1 Therapeutics Inc.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","06998":"亿腾嘉和","BK1161":"生物科技","BK1583":"高瓴概念"},"translate_title":"嘉和生物制药获得NMPA批准Lerociclib治疗晚期乳腺癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06998":0.9},"content_text":"Genor Biopharma Secures NMPA Approval for Lerociclib to Treat Advanced Breast Cancer\n    \n\n        Genor Biopharma Holdings Ltd. has announced that the China National Medical Products Administration (NMPA) has granted approval for the new drug application of Lerociclib (GB491). This novel, highly potent, selective oral bioavailable cyclin-dependent kinases 4 and 6 inhibitor (CDK4/6i) has been co-developed by Genor Biopharma and G1 Therapeutics Inc. It is designed for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer. Lerociclib will be used in combination with an aromatase inhibitor as initial endocrine-based therapy, or with fulvestrant in patients whose disease has progressed following endocrine therapy. This approval represents a significant milestone for Genor Biopharma and showcases the successful collaboration with G1 Therapeutics Inc.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genor Biopharma Holdings Ltd. published the original content used to generate this news brief on May 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}